New drug: An oral antibiotic that’s also an anti-inflammatory
Pharmacies and pharmacies across the country are scrambling to find new ways to make their pharmacy shelves more patient-friendly.
A drug made from the bacterium Bacillus subtilis that can fight infections is now the subject of a patent application, with the patent application being filed on Thursday.
It’s not a brand new antibiotic, however.
Bacillus subtillis is used in several other countries, including in the United Kingdom, France and the United States.
It has been shown to be a powerful antibiotic in humans, but not in animals, and it hasn’t been proven to be effective in humans.
The new drug, a compound known as Lactobacillus, has been in development since late 2015, but it was first reported last year.
In the patent filing, which is a draft of a proposed patent, the drug’s makers claim that Lactophilus is effective against the majority of bacterial infections in humans and animals.
That’s good news for the industry, which has struggled to find a solution to an ever-increasing bacterial load.
“Lactophillus is the first antibiotic that has shown to show clinical efficacy in humans against most commonly encountered bacterial infections, including common colds, diarrhea, pneumonia, and urinary tract infections,” the patent reads.
Lactobactam is currently a popular antibiotic prescribed for people with uncomplicated urinary tract infection.
It’s used in the US for treating urinary tract bacteria such as strep throat, Crohn’s disease and meningitis.
While the drug can be used as a standalone drug, its ability to fight other bacterial infections has proven beneficial to many.
Some of the most popular antibiotic-resistant infections, such as MRSA, enterococci and Escherichia coli, are more resistant to the Lactofax than other bacteria.
With a patent, it’s possible that other companies may develop similar antibiotics that can be sold as an oral supplement, and that could also help keep the industry on track.
Currently, Lactocast, a supplement that’s manufactured by New Frontier Laboratories, sells for $35.99 per month.
Patent filings like these can help explain why the FDA has approved LactoScan, a tablet that can treat bacterial infections.
Lactococcal is also used as an antiinfectant, and a study found that it also has the ability to prevent MRSA from growing.
But as a drug, Lactic Acid is only used once a month, and its effectiveness can vary based on the type of bacteria.
Lactic acid also has been linked to diarrhea in some patients, and in a 2014 study, it was found to inhibit the growth of the antibiotic carbapenem-resistant Enterobacteriaceae, or CRE.
Although it has not been proven that Lactic Acids will be as effective against bacteria as Lactic Bitartrate, its patent filing makes it clear that it’s unlikely to be too far off.